Alkahest announced the appointments of Karl G. Trass as vice president of Regulatory Affairs and Jonas Hannestad, M.D., Ph.D. as senior medical director.
"We are delighted to further expand our development team as we work to bring innovative medicines to patients with Alzheimer's Disease, Parkinson's Disease and other serious diseases of aging," said Helen Jenkins, Alkahest's chief operating officer.
Karl brings to Alkahest more than 20 years of experience providing global regulatory strategic leadership in both pharmaceutical and biotechnology companies. He joins the company from Tobira Therapeutics where he was also vice president of Regulatory Affairs.
Jonas also has more than 20 years of experience in the field of neuroscience at both academic and biopharmaceutical organizations and is a noted authority in PET imaging in neuroinflammatory and other neurological disorders including the effect of systemic factors on the brain. Dr. Hannestad will maintain his appointment as Adjunct Assistant Professor of Psychiatry at the Yale University School of Medicine, and will be responsible for Alkahest's clinical programs in Alzheimer's and Parkinson's Disease.